Atlas Trials

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Clinical trial NCT05678673 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05678673
Sponsor
Exelixis
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non-Clear Cell Renal Cell Carcinoma
Start date
2023-01-01
Primary completion
2026-12-15
Enrollment
317

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.